Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
Lei Pan, Wenzhou Wang, Marisela Sheldon, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3390-3390
Open Access | Times Cited: 21

Showing 21 citing articles:

Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis
Mengchao YANG, Yufeng Mu, Xiaoyun Yu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116783-116783
Open Access | Times Cited: 10
Chitosan and hyaluronic acid in breast cancer treatment: Anticancer efficacy and nanoparticle and hydrogel development
Yanlin Jiang, Yu Cao, Yiqun Yao, et al.
International Journal of Biological Macromolecules (2025) Vol. 301, pp. 140144-140144
Closed Access | Times Cited: 1
Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells
Sama W.A. Helmy, Amal Kamal Abdel‐Aziz, Eman M.E. Dokla, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116255-116255
Closed Access | Times Cited: 7
Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA
Seyedeh Tayebeh Ahmadpour, Charlotte Orré, Priscila Bertevello, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15897-15897
Open Access | Times Cited: 13
Osteopontin, a Key Multifaceted Regulator in Tumor Progression and Immunomodulation
Venketesh K. Panda, Barnalee Mishra, Angitha N Nath, et al.
(2024)
Open Access | Times Cited: 5
Thymoquinone and Metabolic Reprogramming in Breast Cancer: A New Dimension From Proteomic Analysis
Tuğcan Korak, Merve Gülşen Bal Albayrak, Murat Kasap, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 1
Closed Access
Research progresses and hotspots on glucose metabolic reprogramming in breast cancer: a bibliometric analysis over the past two decades
Lei Huang, Wenyue Zhao, Lamei Sun, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Metabolomic Profiling of Disease Progression Following Radiotherapy for Breast Cancer
Alexandra N. McMahon, Isildinha M. Reis, Cristiane Takita, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 891-891
Open Access
Hexokinase2-engineered T cells display increased anti-tumor function
Raphaëlle Toledano Zur, Shiran Didi Zurinam, Maria Radman, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
CDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status
Katherine Krupa, Anna Liszcz-Tymoszuk, Natalia Czerw, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1039-1039
Open Access
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway
Wang Bei, Zixuan Wang, Zhizhen Zhou, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
An in- vitro measurement for the toxicity of peptides inhibit hexokinase II in breast cancer cell lines
Faranak Karamifard, Ali Dadbinpour, Mahta Mazaheri
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The role of circular RNAs in glucose metabolic reprogramming: impact on cancer progression and therapeutic implications in breast cancer
Yiran Liang, Qifeng Yang
Journal of Cancer Metastasis and Treatment (2025)
Open Access
Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation
Venketesh K. Panda, Barnalee Mishra, Angitha N. Nath, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1527-1527
Open Access | Times Cited: 3
Functions of Differentially Regulated miRNAs in Breast Cancer Progression: Potential Markers for Early Detection and Candidates for Therapy
Kumar Subramanian, Raghu Sinha
Biomedicines (2024) Vol. 12, Iss. 3, pp. 691-691
Open Access | Times Cited: 2
Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma
Sirayot Areewong, Orawan Suppramote, Sunisa Prasopporn, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
A molecular signature for the G6PC3/SLC37A2/SLC37A4 interactors in glioblastoma disease progression and in the acquisition of a brain cancer stem cell phenotype
Sima Torabidastgerdooei, Marie‐Eve Roy, Borhane Annabi
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 4
A PET‐Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers
Stefano Confalonieri, Bronislava Matoskova, Rosa Pennisi, et al.
Advanced Science (2024) Vol. 11, Iss. 28
Open Access | Times Cited: 1
Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer
Chiara Papulino, Ugo Chianese, Ahmad H. Ali, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Insights into Metabolic Reprogramming in Tumor Evolution and Therapy
Ching‐Feng Chiu, Jonathan Jaime G. Guerrero, Ric Ryan H. Regalado, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3513-3513
Open Access | Times Cited: 1
Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype
Elena I. Dyachenko, Lyudmila V. Bel’skaya
Current Issues in Molecular Biology (2024) Vol. 47, Iss. 1, pp. 4-4
Open Access
Page 1

Scroll to top